Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Frequently asked questions
What sector does Oramed Pharmaceuticals Inc (OJU1) operate in?
Oramed Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oramed Pharmaceuticals Inc (OJU1) current stock price?
As of the latest data, Oramed Pharmaceuticals Inc stock price is €3.61, with a previous close of €3.60. Oramed Pharmaceuticals Inc gained €0.02 in the last trading session, representing a 0.42% increase.
What is Oramed Pharmaceuticals Inc (OJU1) current market capitalization?
Oramed Pharmaceuticals Inc market cap is approximately 147.74 million.
What is Oramed Pharmaceuticals Inc (OJU1) Earnings Per Share (EPS)?
The trailing EPS is €3.56.
What is Oramed Pharmaceuticals Inc (OJU1) Price-to-Earnings (P/E) ratio?
Oramed Pharmaceuticals Inc current P/E ratio is 1.01.
What is Oramed Pharmaceuticals Inc (OJU1) EBITDA?
Oramed Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.35 million.
Does Oramed Pharmaceuticals Inc (OJU1) pay dividends?
Yes. Oramed Pharmaceuticals Inc pays annual dividends with an annualized yield of 5.54% and an estimated annual payout of €0.22 per share.
When is the next ex-dividend date for Oramed Pharmaceuticals Inc (OJU1)?
The next ex-dividend date is scheduled for January 16, 2027.
When is Oramed Pharmaceuticals Inc (OJU1) next earnings report?
Oramed Pharmaceuticals Inc is expected to release its next earnings report on August 31, 2026.
What is Oramed Pharmaceuticals Inc (OJU1) beta (volatility) score?
Oramed Pharmaceuticals Inc has a beta of 1.276, suggesting it is more volatile than the market.
